Abstract 240P
Background
The efficacy of first-line combination immuno-oncology therapy (IO) with ipilimumab plus nivolumab in metastatic renal cell carcinoma was demonstrated in the international phase III randomized CheckMate-214 trial. We also realized that the prognosis of Inter/Poor risk metastatic renal cancer could be extended in real clinical practice.
Methods
At Juntendo Univ. Hosp., Ipilimumab plus Nivolumab was used as first-line combination therapy for total 30 patients, including 27 patients with real-world Inter/Poor risk metastatic renal cell carcinoma from Jan/2019 to Aug/2023 and 3 patients enrolled in the international phase III study CheckMate-214. Efficacy in overall survival and safety, mainly immune-related adverse events(irAE), were retrospectively analyzed.
Results
Median age was 63 years (27-79), 37% (11/30) had prior nephrectomy. The most common metastatic lesions were lung (60%), bone (47%), and lymph node (37%). Three cases of hemodialysis were also included. The IMDC risk classification was Favor: Inter: Poor =2: 18: 10 cases. Total 80% (24/30) of cases were able to complete 4 cycles of ipilimumab. The average duration of IO treatment was 15.8 months (2-63). And the average duration of response was 27.3 months (2-92). During the mean follow-up period of 26.5 months (2-94), 6 cases died from cancer and 2 deaths from other causes. Among the cancer death cases, 4 of 6 cases were non-clear cell RCC. Deferred cytoreductive nephrectomy (DCN) could be performed in 2 cases in which metastatic lesions were controlled by IO-combo therapy. DCN was also performed in one patient withdrawn due to irAE, and surgical complete response (CR) was obtained. A total of 23% (7/30) had irAEs that forced IO administration to be discontinued. For irAEs of endocrine disorders, such as adrenal insufficiency and diabetes type 1, IO treatment could be continued with appropriate hormone replacement.
Conclusions
IO-Combo treatment for metastatic RCC was performed effectively and safely in Japanese patients. Surgical CR may be achieved with DCN after IO combination therapy even in poor-risk patients, but there is a possibility that Ipilimumab plus Nivolumab treatment has weak efficacy for non-clear cell RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract